Clopidogrel clinical trials
Clopidogrel is named as an intervention in 54 current clinical trials in our China, South Korea, Canada, Switzerland, Egypt, Germany, Netherlands, Brazil, France, Spain, Italy, Israel, Sweden, Denmark, Mexico, Ireland, India, Belgium, Czechia, Portugal, Japan, Australia, USA, Norway, Poland and Singapore registers. 40 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Yonsei University (3). The most-studied condition is Ischemic Stroke. The EU clinical trials register (CTIS) separately lists 4 authorised or ongoing trials.
Where Clopidogrel is approved
All regulators →Of the three regulators tracked here, the first to approve Clopidogrel was the EU, on 14 Jul 1998.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Clopidogrel
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Clopidogrel works
All drug targets →- Purinergic receptor P2Y12 antagonist AntagonistTarget: P2RY12 purinergic receptor P2Y12ChEMBL only
- Arterial thrombosisPhase 3
- COVID-19Phase 3
- Myocardial necrosisPhase 3
- Non-ST Elevation Myocardial InfarctionPhase 3
- ST Elevation Myocardial InfarctionPhase 3
- Acute myocardial infarctionPhase 3
- Age-related macular degenerationPhase 3
- Angina pectorisPhase 3
- Angina unstablePhase 3
- Aortic stenosisPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1771, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7150, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Clopidogrel
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 3 technology appraisals of Clopidogrel. 2 are current, and 2 of these recommend it for at least some patients. 1 older appraisal was replaced or withdrawn.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events NICE TA210 | Recommended Optimised | 15 Dec 2010 | Current |
| Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events NICE TA90 | Optimised | 25 May 2005 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Clopidogrel
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 12 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: Clopidogrel Zentiva (previously Clopidogrel Winthrop), Iscover, Plavix, Clopidogrel BGR (previously Zylagren) (generic), Clopidogrel HCS (generic), Clopidogrel Krka (generic), Clopidogrel Krka d.d. (previously Zopya) (generic), Clopidogrel TAD (generic) and 4 moreEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Clopidogrel
- ATC code
- B01AC04
- ChEMBL
- CHEMBL1771
- DrugBank
- DB00758
- PubChem CID
- 60606
- CAS number
- 113665-84-2
- FDA UNII
- A74586SNO7
- Wikidata
- Q410237
- Wikipedia
- Clopidogrel
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Clopidogrel
54 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Clopidogrel in the EU trials register (CTIS)
4 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Clopidogrel. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Clopidogrel across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
12 single-substance products containing Clopidogrel on the HPRA medicines list.
- Clodel 75 mg film-coated tabletsRowex Limited, · PA0711/166/001 · Marketed
- Clopidogrel Clonmel 75mg Film-coated TabletsClonmel Healthcare Ltd · PA0126/279/001 · Marketed
- Clopidogrel Zentiva 75 mg film-coated tabletsZentiva k.s. · EU/1/08/465/1-14
- Clopidogrel BGR 75 mg film-coated tabletsLaboratoires BIOGARAN · EU/1/09/558/1-12
- Clopidogrel Krka 75 mg film-coated tabletsKRKA, d.d., Novo mesto · EU/1/09/556/1-9
Supply shortages
No entry for Clopidogrel in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Clopidogrel
78 conditionsAll 78 conditions
| Condition (as registered) | Trials |
|---|---|
| Ischemic Stroke | 8 |
| Coronary Artery Disease | 8 |
| Percutaneous Coronary Intervention | 5 |
| Acute Coronary Syndrome | 4 |
| Atrial Fibrillation | 4 |
| Stroke, Ischemic | 3 |
| Stroke | 3 |
| Acute Coronary Syndromes (ACS) | 2 |
| Peripheral Arterial Disease | 2 |
| Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | 2 |
| Mitral Regurgitation | 2 |
| Acute Coronary Syndromes | 2 |
| Cerebral Infarction | 2 |
| Respiratory Tract Diseases | 1 |
| Influenza (Pandemic) | 1 |
| Influenza | 1 |
| Community Acquired Pneumonia | 1 |
| Recent Myocardial Infarction | 1 |
| Recent Stroke | 1 |
| Small Vessel Cerebrovascular Disease | 1 |
| White Matter Hyperintensity | 1 |
| Minor Ischemic Stroke | 1 |
| Kawasaki Disease | 1 |
| Coronary Artery Aneurysm | 1 |
| Chronic Coronary Syndrome | 1 |
| Transient Ischemic Attack | 1 |
| Stroke, Acute | 1 |
| Large-Artery Atherosclerosis (Embolus/Thrombosis) | 1 |
| SCAD | 1 |
| ACS (Acute Coronary Syndrome) | 1 |
| Covert Brain Infarction | 1 |
| CLTI Defined as Rutherford Category 4 or 5 | 1 |
| Bacteremia Due to Staphylococcus Aureus | 1 |
| Clopidogrel, Poor Metabolism of | 1 |
| Carotid Stenosis | 1 |
| CYP2C19 Polymorphism | 1 |
| Aortic Valve Stenosis | 1 |
| Cardiovascular Diseases | 1 |
| Heart Diseases | 1 |
| Heart Valve Diseases | 1 |
| Antithrombotic Therapy | 1 |
| Percutaneous Coronary Interventions | 1 |
| Antiplatelet Therapy | 1 |
| Cardiovascular Prevention | 1 |
| Cardiac Allograft Vasculopathy | 1 |
| Heart Transplant | 1 |
| Left Atrial Appendage Closure | 1 |
| Thrombosis | 1 |
| TIA | 1 |
| Staphylococcus Aureus Endocarditis | 1 |
| Staphylococcus Aureus Septicemia | 1 |
| Staphylococcus Aureus Bloodstream Infection | 1 |
| Intracranial Atherosclerosis | 1 |
| Takayasu Arteritis (TAK) | 1 |
| Vasculitis, Systemic | 1 |
| Assessment of Platelet Aggregability in Patients Patients with Non-small Cell Lung Carcinoma | 1 |
| Intracranial Arteriosclerosis | 1 |
| Coronary Artery Ectasia | 1 |
| STEMI - ST Elevation Myocardial Infarction | 1 |
| NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI) | 1 |
| Ischemic Heart Disease | 1 |
| High Bleeding Risk | 1 |
| Cardiac Event | 1 |
| Peripheral Artery Disease | 1 |
| Bleeding | 1 |
| Carotid Artery Diseases | 1 |
| Type 2 Diabetes | 1 |
| Atherosclerosis | 1 |
| Myocardial Infarction (MI) | 1 |
| ST-Segment Elevation Myocardial Infarction(STEMI) | 1 |
| NSTEMI - Non-ST-Segment Elevation Myocardial Infarction | 1 |
| AF - Atrial Fibrillation | 1 |
| Stenosis Artery | 1 |
| Ischemic | 1 |
| Intracrnaial Arterioscelrosis | 1 |
| Patent Foramen Ovale | 1 |
| Antiphospholipid Syndrome | 1 |
| Arterial Thrombosis | 1 |
Sponsors
lead sponsor per trial+ 29 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Clopidogrel trials
How many clinical trials are testing Clopidogrel?
54 current trials in our China, South Korea, Canada, Switzerland, Egypt, Germany, Netherlands, Brazil, France, Spain, Italy, Israel, Sweden, Denmark, Mexico, Ireland, India, Belgium, Czechia, Portugal, Japan, Australia, USA, Norway, Poland and Singapore registers name Clopidogrel (also registered as SUB13395MIG) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Clopidogrel trials recruiting patients?
Yes. 40 of the 54 trials are recruiting: 14 with sites in China, 9 with sites in South Korea, 6 with sites in Canada, 3 with sites in Switzerland, 3 with sites in Egypt, 2 with sites in Germany, 2 with sites in Netherlands, 2 with sites in France, 1 with sites in Spain, 2 with sites in Italy, 1 with sites in Israel, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Mexico, 1 with sites in Ireland, 1 with sites in India, 1 with sites in Belgium, 1 with sites in Czechia, 1 with sites in Portugal, 1 with sites in Japan, 1 with sites in Australia, 1 with sites in USA, 1 with sites in Norway and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Clopidogrel clinical trials?
Yonsei University (3), Kafrelsheikh University (3), Chinese Academy of Medical Sciences, Fuwai Hospital (2) and Xijing Hospital (2), among 44 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Clopidogrel clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Clopidogrel licensed in Ireland?
Yes. The HPRA medicines list includes 12 single-substance products containing Clopidogrel, for example Clodel 75 mg film-coated tablets (Rowex Limited,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Clopidogrel shortage?
Not in the lists we track: Clopidogrel has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Clopidogrel works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Clopidogrel works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Clopidogrel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.